CLINICAL AND ECONOMIC IMPACT OF INITIATING DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN EUROPE

Author(s)

Rock M1, Dort T2, Snyder S3, Gitlin M3
1Biogen, Inc, Cambridge, MA, USA, 2Biogen, Baar, Switzerland, 3BluePath Solutions, Los Angeles, CA, USA

OBJECTIVES: To evaluate the economic impact in Europe (Sweden, France, Germany, UK, Spain, and Italy) of beginning and continuing treatment with dimethyl fumarate (DMF) versus initiating treatment with glatiramer acetate (GA) and switching to DMF after treatment failure.

METHODS: A Markov model with 10 health states (EDSS scores from 0 to 9) and death over a lifetime horizon in MS patients using annual cycles was used to compare the outcomes of treated RRMS patients from a societal perspective. The model incorporates the ability to fail GA and switch to DMF based on incurring ≥ 2 relapses within a 12-month period. Efficacy inputs were estimated from a mixed treatment comparison, including hazard ratios for 6-month confirmed disability progression, and risk ratios for annualized relapse rates. Economic inputs included the costs of treatment, relapse, and disability status. All estimates reflect costs in 2018 Krona (Sweden), Euros (France, Germany, Italy, Spain) and British Pounds (UK).

RESULTS: Among RRMS patients initially treated with DMF in Sweden, Germany, France, and Italy, cost offsets were observed in the amount of kr385,356 for Sweden, €9,910 for France, €46,414 for Germany, and €825 for Italy. In addition, initiating DMF reduced relapses by 2.3 to 2.4, increased the time spent within EDSS states < 6 by ~1 year, and resulted in a 0.48 to 0.68 gain in quality-adjusted life years (QALYs). Cost increases were observed for Spain (€7,442) and the UK (£56,949). Despite increased costs, a reduction of 2.1 to 2.3 relapses, 0.75 to 0.92 year increase in the time spent with EDSS < 6, and 0.48 to 0.50 gain in QALYs, were observed per patient for Spain and UK.

CONCLUSIONS: DMF as the initial treatment for RRMS patients before initiating and failing on GA results in improved clinical benefits across all European countries with the majority demonstrating economic savings.

Supported by: Biogen

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PND19

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison/Effectiveness/Utility/Benefit Analysis

Disease

Neurological Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×